First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.

The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.

The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.

But the former is paying a fraction of what Merck shelled out for raludotatug.

LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.

BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.

The company will soon start a pivotal trial of its IL-12 gene therapy, but cash is short.